Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Oxford BioMedica ( (GB:OXB) ) just unveiled an announcement.
Oxford Biomedica, a FTSE250-listed cell and gene therapy CDMO, provides viral vector technologies such as its TetraVecta lentiviral system and dual-plasmid AAV platform, underpinned by extensive regulatory and quality capabilities. Its geographically diversified manufacturing footprint in Oxfordshire, Lyon, Strasbourg, Bedford, Massachusetts, and Durham, North Carolina supports global biopharma partners.
The company disclosed that Kathleen Miller, Head of Human Resources and acting Interim Site Head for Bedford Operations, exercised 4,486 restricted share units granted under the 2024 Long Term Incentive Plan at a nil exercise price. She subsequently sold 1,578 ordinary shares on the London Stock Exchange at an average price of £6.091, a routine PDMR dealing that marginally trims but does not materially alter senior management equity exposure.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £1170.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on OXB Stock
According to Spark, TipRanks’ AI Analyst, OXB is a Neutral.
The score is held back primarily by weak financial performance (still loss-making with negative operating/free cash flow despite improvement) and bearish technicals (price below key moving averages with negative MACD and weak RSI). Valuation provides limited support due to negative earnings and no dividend yield data.
To see Spark’s full report on OXB stock, click here.
More about Oxford BioMedica
Oxford Biomedica (OXB) is a global, quality- and innovation-led contract development and manufacturing organisation specialising in cell and gene therapy. The company focuses on viral vector development and manufacturing, including lentiviral, AAV and adenoviral platforms, supporting clients from early-stage development through commercialisation across facilities in the UK, France and the U.S.
Average Trading Volume: 333,652
Technical Sentiment Signal: Buy
Current Market Cap: £747.3M
Find detailed analytics on OXB stock on TipRanks’ Stock Analysis page.